ZBH

Analyst Note: ZBH (Zimmer Biomet Holdings, Inc.)

Date: 2026-06-20 Current Price: $87.97

1. Structural Readiness

• State: Avoid.
• Conservative Entry: Not Available. (Requires a confirmed breakout above the coil resistance level).
• Aggressive/Pre-Breakout Entry: Not Recommended. (Current state is "Forming," which carries execution risk until the breakout is confirmed).
• Breakout Level: Not Defined in Data.
• Current Price: $87.97.
• Extension: Not Defined.
• ATR Context: Current ATR is 2.6% (Productive). This sits within the "productive" range, indicating manageable volatility for sizing, but the lack of a defined breakout level prevents a precise ATR-at-breakout calculation.

2. Thesis Layer

• Thesis Classification: Tactical / Setup-Led.
• Macro Context: There is no named secular thesis attached to this specific setup as of 2026-06-20. The investment case is not driven by a broad macro theme (e.g., "AI in Healthcare" or "Demographic Super-Cycle") but is strictly a function of the structural setup quality and the company's fundamental execution.
• Judgment Criteria: The name must be judged solely on the quality of the setup (coiling structure) and the strength of the business fundamentals (guidance, margin expansion, acquisition integration). No external narrative should be invented to support the trade.

3. Business Overview

• Core Business: Zimmer Biomet Holdings, Inc. is a global leader in orthopedic solutions, treating disorders of bones, joints, and supporting soft tissues. The company serves orthopedic surgeons, neurosurgeons, and healthcare institutions.
• Business Model: The company operates on a consignment model, where approximately 85% of net sales in 2025 were consignment sales. This implies inventory is held at customer sites (hospitals/surgery centers) until the point of use.
• Geographic Exposure: The U.S. is the dominant market, accounting for approximately 95% of net sales in the region. In the International region, France, Germany, Italy, Spain, and the UK collectively accounted for ~50% of sales, while Japan accounted for ~50% of the Asia-Pacific region's sales.
• Recent Strategic Moves (as of 2026):
• Acquisition: On April 21, 2025, the company completed the acquisition of Paragon 28, a leading medical device company focused exclusively on the foot and ankle segment. This acquisition is intended to increase market share in a segment growing faster than others.
• Restructuring: Management approved a "2025 Restructuring Plan" in February 2025 (expanded in December 2025) to reduce costs and transform operations. This plan is expected to result in total pre-tax restructuring charges of approximately $155 million by the end of 2027.
• R&D: As of December 31, 2025, the company employed approximately 2,000 research and development employees worldwide.
• Product Performance (Q1 2026 context):
• U.S. Knee: Growth of 2.2%, driven by a >20% increase in partial knee cases via the Oxford Partial Cementless Knee.
• U.S. Hip: Growth of 5%, driven by the "hip triple play" (OrthoGrid, HAMMR, surgical impact), with the triple play representing nearly 40% of U.S. hip temps.
• Technology & Data: Grew nearly 12%, driven by ROSA and TMINI sales.
• Sports Medicine: Represented 12% of S.E.T. product category net sales in 2025.

4. Archetype and Conviction

• Archetype: Quality Compounder.
• *Fit:* The company demonstrates consistent revenue growth (organic constant currency revenue growth guidance of 1% to 3% for 2026), expanding margins (operating margins expected to be better than anticipated, down <50 bps from 2025), and strong free cash flow generation (FCF growth expected 9% to 11%). The acquisition of Paragon 28 and the restructuring plan indicate a management team actively optimizing the business for long-term compounding.
• Valuation & Fundamentals:
• Management has raised full-year 2026 adjusted EPS guidance to $8.40–$8.55 (from $8.30–$8.45).
• The company is investing in its U.S. commercial channel and absorbing dilution from the Paragon 28 acquisition while still delivering margin expansion.
• The "Quality Compounder" label is supported by the ability to grow FCF and EPS simultaneously despite heavy investment and acquisition integration.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro tailwind).
• Evidence Quality: High (Strong earnings guidance, clear acquisition integration, specific product traction).
• Structural Quality: Moderate (ATR is productive at 2.6%, but the setup is "Forming," not "Confirmed").
• Setup Readiness: Low (Price is in a "Forming" state; no breakout has fired).
• Rerating Potential: Moderate (Dependent on the successful execution of the restructuring plan and the realization of the Paragon 28 synergies).

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• A significant miss on the 2026 EPS guidance (currently $8.40–$8.55) or FCF growth (9%–11%).
• Failure to integrate Paragon 28 or unexpected cost overruns in the $155M restructuring plan.
• What Would Strengthen:
• A confirmed breakout above the coil resistance level (price action confirmation).
• Further upward revisions to 2026 guidance.
• Continued strong growth in the "hip triple play" and ROSA/TMINI technology segments.
• Gaps in Evidence:
• Missing Sector/Industry Labels: The specific industry classification is not provided in the evidence block (though "Healthcare" is noted).
• Missing Family/Coil Details: The specific "Family" of the setup is not named.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Management raised 2026 EPS guidance to $8.40-$8.55 and FCF growth to 9%-11%; Paragon 28 acquisition completed in April 2025 to expand foot and ankle share; U.S. hip franchise grew 5% driven by technology integration. Key risks: Setup is in "Forming" state with no breakout fired; 2025 Restructuring Plan involves $155M in charges through 2027; 85% of sales are consignment, creating inventory visibility risks; U.S. market concentration at 95% of regional sales. Sizing hint: Position size should be minimal or zero until a confirmed breakout occurs; current volatility (2.6% ATR) is manageable but setup readiness is low. Expected path: Management expects 2026 operating margins to improve slightly despite acquisition dilution; U.S. knee and hip segments expected to continue growth; restructuring charges to be recognized through 2027. Expected horizon: 3 to 6 months for setup confirmation or invalidation.